海外の治験の状況「%E8%84%B3%E5%8D%92%E4%B8%AD」での検索結果
261件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Recruiting
- Los aMiGoS: Is LactOSe tolerance impacted by repeated exposure to A2 beta-casein MIlk, with effects on Gut COmfort Symptoms
- Impaired digestion;Lactose intolerance
- New Zealand
- 2017-10-31
Not recruiting
- Oral Administration of Anti-CD3 Monoclonal Antibody in Non-responder Genotype-I Chronic Hepatitis C Subjects
- Chronic Hepatitis C
- Austria, Poland
- 2011-10-23
Not Recruiting
- UVA 1 therapy versus 5-MOP UVA photochemotherapy for patients with severe generalized atopic dermatitis - UVA 1 vs 5-MOP UVA for AD
- Severe generalized atopic dermatitis MedDRA version: 9.1 Level: LLT Classification code 10003639 Term: Atopic dermatitis
- Austria
- 2007-03-14
Not recruiting
- Oral Administration of Four Lactobacillus Species Preparation to Improve the Quality of the Neovaginal Flora in Male to Female Transsexual Patients
- Reduction or Absence of Lactobacilli in Neovaginal Flora
- Austria
- 2012-10-11
Not Recruiting
- A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-MASKED STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF SHP640 (PVP-IODINE 0.6% AND DEXAMETHASONE 0.1%) OPHTHALMIC SUSPENSION COMPARED TO PVP-IODINE AND PLACEBO IN THE TREATMENT OF ADENOVIRAL CONJUNCTIVITIS.
- -B301 +Conjunctivitis due to adenovirus (H13.1*) +Conjunctivitis due to adenovirus (H13.1*);+Conjunctivitis due to adenovirus (H13.1*)
- Australia, Austria, Canada, Colombia, Estonia, France, Germany, Hungary, India, Israel, Italy, Philippines, Poland, South Africa, Spain, United Kindgdom, United States
- 2018-08-13
Not Recruiting
- A randomised, double-blind, placebo controlled, parallel group 24 week study to assess the efficacy and safety of BI 1356 (5 mg) in combination with 30 mg pioglitazone (both administered orally once daily), compared to 30 mg pioglitazone plus placebo in drug naive or previously treated type 2 diabetic patients with insufficient glycaemic control. - Efficacy vs. PBO as initial combination therapy with pioglitazone
- Patients with type 2 Diabetes Mellitus with insufficient glycaemic control. MedDRA version: 9.1 Level: LLT Classification code 10045242 Term: Type II diabetes mellitus
- Austria, Greece, Hungary, Portugal, Spain
- 2008-01-22
Authorised
- The efficacy and safety of a daily oral administration of S06911 (strontium ranelate 2g/vitamin D3 1000 IU fixed combination) on vitamin D insufficiency in the treatment of osteoporotic postmenopausal women and men. A prospective, international phase III study with a 6-month double-blind period to assess the efficacy and safety of a daily oral administration of S06911 versus S12911 (strontium ranelate 2g) and a 6-month open-labelled extension for a subgroup of patients to assess safety of a daily oral administration of S06911.
- Osteoporotic men and postmenauposal women MedDRA version: 12.0 Level: LLT Classification code 10031283 Term: Osteoporosis fracture MedDRA version: 12.0 Level: LLT Classification code 10031285 Term: Osteoporosis postmenopausal
- Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Hungary, Poland, Slovakia, Spain, United Kingdom
- 2009-10-26
Authorised
- This is a study to help understand how Baricitinib compares to placebo (a tablet that does not contain any active medicine) in adults with moderate to severe atopic dermatitis, also known as atopic eczema
- Atopic Dermatitis MedDRA version: 20.0 Level: LLT Classification code 10003639 Term: Atopic dermatitis System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Argentina, Australia, Austria, Hungary, Israel, Japan, Korea, Republic of, Poland, Spain, Switzerland
- 2017-10-05
Not Recruiting
- Study Title: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis (RRMS) - Allegro
- Relapsing Remitting Multiple Sclerosis (RRMS) MedDRA version: 9.1 Level: PT Classification code 10028245 Term: Multiple sclerosis
- Austria, Bulgaria, Czech Republic, Estonia, France, Germany, Hungary, Italy, Latvia, Lithuania, Netherlands, Portugal, Spain, Sweden, United Kingdom
- 2007-07-12
Not Recruiting
- A randomized, double-blind, placebo-controlled, 2-arm parallel-group, multicenter study with a 24-week main treatment period and an extension assessing the efficacy and safety of AVE0010 on top of pioglitazone in patients with type 2 diabetes not adequately controlled with pioglitazone. - GETGOAL-P
- Type II diabetes MedDRA version: 10.1 Level: LLT Classification code 10067585 Term:
- Austria, France, Germany, Greece
- 2008-05-26